All In Biotech

Drug Trial Radar · NCT07053384

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

107

Actual

Start

Jul 10, 2025

Primary completion

Jan 22, 2027

Study completion Sep 6, 2028

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).

Conditions

  • HIV Infections

Interventions

  • VH3810109Biological

    VH3810109 will be administered.

  • Fostemsavir (FTR)Drug

    Fostemsavir will be administered.

  • SOC INSTI-based ARTDrug

    A SOC INSTI-based ART regimen will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cellsTime frame: From Baseline (Day 1) to Month 12

Locations

41 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Ghent, Oost-Vlaanderen, Belgium

  • GSK Investigational Site

    Hvidovre, Capital Region, Denmark

  • GSK Investigational Site

    Aarhus N, Central Jutland, Denmark

  • GSK Investigational Site

    Rotterdam, Netherlands

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Córdoba, Spain

  • GSK Investigational Site

    La Laguna Santa Cruz, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Palma de Mallorca, Spain

  • GSK Investigational Site

    Palma de Mallorca, Spain

  • GSK Investigational Site

    Seville, Spain

  • GSK Investigational Site

    Valencia, Spain

  • GSK Investigational Site

    Valencia, Spain

  • GSK Investigational Site

    Pozuelo de Alarcón, Madrid, Spain

  • GSK Investigational Site

    London, United Kingdom

  • GSK Investigational Site

    London, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.